A Trial of Degarelix in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Goserelin acetate
Drug: Degarelix

Registration Number: NCT00946920

Lead Sponsor: Ferring Pharmaceuticals

Brief Summary: A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 859

Inclusion Criteria

18 years or older.
Has a histological confirmed prostate cancer Gleason graded).
Has a screening testosterone above 2.2 ng/mL.
Rising prostate-specific antigen (PSA).
Has Eastern Cooperative Oncology Group (ECOG) score of ≤ 2.
Has a life expectancy of at least one year.

Exclusion Criteria

Current or previous hormone therapy.
Has received therapy with finasteride and dutasteride within 12 weeks and 25 weeks, respectively, prior to screening.
Has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
Has a heart insufficiency.
Has a previous history or presence of another malignancy, other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last five years.
Has a clinically significant medical condition (other than prostate cancer) including, but not limited to, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease and alcohol or drug abuse or any other condition which may affect the patient's health or the outcome of the trial as judged by the Investigator.
Has received an investigational drug within the last 28 days before the Screening Visit or longer if considered to possibly influencing the outcome of the current trial.
Is candidate for curative therapy, i.e. radical prostatectomy or radiotherapy.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Goserelin acetate	Goserelin acetate	-
Degarelix 240 mg/480 mg	Degarelix	-

Primary Outcome Measures

Name	Time	Method
Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix	From Day 28 to Day 364	This co-primary outcome measure was used to demonstrate that degarelix is effective with respect to achieving and maintaining testosterone suppression to castrate levels, evaluated as the proportion of patients with testosterone suppression ≤0.5 ng/mL from Day 28 to Day 364.
Difference in Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) Between Degarelix and Goserelin	Day 3 to Day 364	This co-primary outcome measure was used to establish non-inferiority of degarelix as compared to goserelin with regard to achieving and maintaining testosterone suppression at castrate levels (≤0.5 ng/mL) from Day 3 to Day 364, using a non-inferiority margin of 5 percentage points.

Secondary Outcome Measures

Name	Time	Method
Serum Levels of Testosterone Over Time	Baseline and after 1, 2, 3, 6 and 13 months	Median testosterone levels are presented as absolute values at Baseline (in Baseline measures) and after 1, 2, 3, 6 and 13 months (below). One treatment month equals 28 days.
Percent Change in Serum Levels of Prostate-specific Antigen (PSA) Over Time	Baseline and after 1, 2, 3, 6 and 13 months	Serum PSA levels are presented as mean percent change from Baseline (in Baseline measures) after 1, 2, 3, 6 and 13 months. One treatment month equals 28 days.
Change in Health-related Quality of Life (HRQoL), as Measured by Short Form-36 (SF-36) Score at Month 10 and Month 13 Compared to Baseline	At baseline, 10 months and 13 months	The SF-36 is a multi-purpose, short-form health survey with only 36 questions and with a minimum score of 0 and a maximum score of 100. The higher score the better health. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. The SF-36 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments.
Change in International Prostate Symptom Score (IPSS) Score at Months 1, 4, 7, and 13 Compared to Baseline	At baseline, 1 month, 4 months, 7 months and 13 months	IPSS is used to assess severity of lower urinary tract symptoms and to monitor the progress of symptoms once treatment has been initiated. It contains 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5 (i.e. the minimum total score is 0 and the maximum is 35). A score of "0" corresponds to a response of "not at all" for the first six symptoms and "none" for nocturia, and a score of 5 corresponds to a response of "almost always" for the first six symptoms and "5 times or more" for nocturia.

Trial Locations

Locations (124): Urology Centers Of Alabama
🇺🇸
Homewood, Alabama, United States
Arkansas Urology
🇺🇸
Little Rock, Arkansas, United States
Urology Associates of Central CA
🇺🇸
Fresno, California, United States
Medresearch
🇺🇸
La Mesa, California, United States
South Orange County Medical Research Center
🇺🇸
Laguna Hills, California, United States
Atlantic Urology Medical Group
🇺🇸
Long Beach, California, United States
Anschutz Cancer Pavillion
🇺🇸
Aurora, Colorado, United States
The Urology Center of Colorado
🇺🇸
Denver, Colorado, United States
Urological Associates of Bridgeport, P.C.
🇺🇸
Trumbull, Connecticut, United States
Urology Associates of Dover, PA
🇺🇸
Dover, Delaware, United States
Scroll for more (114 remaining)
Urology Centers Of Alabama
🇺🇸Homewood, Alabama, United States